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Increased monocyte tissue factor (mTF) expression occurs in
many inflammatory conditions, and its behaviour has been investi-
gated in animal and human cancer. Circulating mononuclear cells
from tumour-bearing animals have significantly more TF activity
than those from control animals (Lorenzet et al, 1983). Patients
with cancer have significantly higher levels compared with normal
controls (Edwards et al, 1981; Morgan et al, 1988; Carvalho, 1995;
Lwaleed et al, 1997) and cultured monocytes from cancer patients
express increased amounts of TF compared to normal subjects
(Edwards et al, 1981). Furthermore, mTF levels were linearly
correlated with other markers of in vivo coagulation activation (as
measured by elevation of fibrinogen peptide A level) and tumour
burden (Edwards et al, 1981; Morgan et al, 1988; Auger and
Mackie, 1987) suggesting that increased fibrin formation in vivo is
at least partly dependent on mTF expression.
TF is a single-chain, integral plasma membrane glycoprotein
with no intrinsic protease activity (Bach et al, 1981; Guha et al,
1986). TF serves as a receptor and essential co-factor for plasma
factors VII and VIIa in rapid activation of factors X and IX
(Nemerson and Bach, 1982). Thus TF is the principle physiolog-
ical initiator of blood coagulation (Nemerson, 1992). Since mono-
cytes are the only blood cells that are capable of synthesizing TF
(Østerud and Bjorkild, 1982), the emergence of procoagulant
activity (PCA) in response to stimulants such as lipopolysacchride
(LPS) in whole blood level might be of clinical significance.
Dasmahapatra et al (1987), using a whole blood re-calcification
time showed an increased level of LPS-induced mTF in patients
with various tumours and suggested that this could be used to
distinguish, with some certainty, patients with malignant diseases
from those with benign non-inflammatory diseases. Contrino et al
(1996), demonstrated using both immunohistochemical technique
and a novel probe for functional TF, that TF expression by
endothelial cells is present only in the blood vessels of malignant
breast lesions but not in the vessels of benign breast lesions. Thus
both studies demonstrate an association between TF expression
and the malignant phenotype, although the TF detected is on host
cells either circulating or embedded in the tumour stroma. In
contrast, Østerud and Due (1984) failed to find significant differ-
ences in mTF levels or indeed any other coagulation parameters
between patients with malignant or benign tumours. Mellor et al
(1989) reported higher whole blood PCA in breast and colorectal
cancer patients compared to normal controls, but there was no
distinction between malignant and benign surgical control groups.
The latter studies, however, may not have paid enough attention to
the benign groups since inflammatory conditions may cause
similar rises in mTF levels (Edwards et al, 1987). Indeed Parmar et
al (1990) showed a significant difference in whole bood PCA
between cancer and non-cancer surgical groups, with cancer
groups demonstrating higher levels.
While some have measured mTF PCA in whole blood
(Dasmahapatra et al, 1987; Mellor et al, 1989; Parmar et al, 1990),
others have employed laborious techniques to isolate monocytes
(Muller et al, 1985) and have often measured the PCA in
disrupted, rather than intact, cells (Østerud and Due, 1984). In the
present study we employed a two-stage kinetic chromogenic assay
(KCA) which measures mTF on intact cells isolated in a one-step
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activate the cells (Carvalho, 1995). This assay is not significantly
affected by age, gender or smoking habit. Using this assay we
assessed mTF levels in patients with breast and colorectal cancer,
and compared the results with normal controls, surgical controls
and subjects with benign diseases. The effect of inflammatory
conditions on mTF was assessed and mTF levels were correlated
with histological tumour grading or staging and patient survival.
MATERIALS AND METHODS
Controls and patients
Ethical committee approval was obtained for the study from the
Southampton and South West Hampshire Health Commission
Joint Ethical Sub-Committee (submission number 239/93) and
informed consent was sought from each patient. A total of 265
subjects were studied: Patients were admitted into the surgical
wards of Southampton University Hospitals (see Table 1 for
details). Blood samples were taken prior to operation. All patients
had been clinically diagnosed and the histopathology reports were
subsequently reviewed. Tumours were classified according to the
World Health Organization classification for breast cancer and
Dukes’ categorization for colorectal cancer.
Controls and patients
mTF level was assayed using a two-stage KCA (Carvalho, 1995)
which is described below. mTF activity was measured as baseline
(resting cells), after 6h incubation without endotoxin (unstimu-
lated cells) and after 6h incubation with endotoxin (10mg/ml,
Sigma Chemical Company, Pool, Dorset, UK) (stimulated cells) at
37°C and 5% carbon dioxide. TF on the surface of the monocytes
forms a complex with factor VII and Ca2+. The complex activates
factor X to factor Xa which then acts on a specific chromogenic
substrate resulting in the generation of a yellow colour that can
then be measured spectrophotometrically.
Cell preparation
Ten millilitres of venous blood was collected into an ethylene-
diamine-tetra acetic acid (EDTA) tube. The blood samples were then
transferred to Leukoprep™tubes (Becton Dickinson, Oxford, UK)
and centrifuged (within 2h of sample collection) for 15min at
1500–1800 gat room temperature. After centrifugation the plasma
layer was discarded; the buffy coat layer, which contains the
mononuclear cells as well as platelets, was transferred to a
flat-bottomed polystyrene tube (Greiner Labortechnik, Germany).
Cells were then washed three times using cooled sterilized
Dulbecco’s saline buffer (Sigma Chemical Company, Pool, Dorset,
UK). The washed mononuclear cells were then resuspended in
RPMI-1640 medium with L-glutamine (Gibco, UK) and adjusted to 2
´106cells ml–1 and platelet to monocyte ratio of between 4:1 and 6:1.
Assay procedure
A total of 100ml of cell suspension were placed into duplicate wells
in a 96-well flat-bottomed microtitre plate and cells were allowed to
adhere for 10min. The non-adherent cells and the pre-set ratio of
contaminating platelets (see above) were then washed off using cold
saline. To the adherent cells the following reagents were then
added: 60ml of the assay buffer (0.05 Tris, sodium
chloride, pH 7.8), 20ml of calcium chloride (0.025M) and 15ml
(0.75 unit ml–1) of a commercially available clotting factor concen-
trate (Prothromplex TIM4 30U ml–1, Immuno Ltd, Dunton Green,
UK) as a source of factors VII and X. Control wells contained the
above reagents, but with 15ml of factor X buffer instead of
prothromplex for background subtraction. The plate was then incu-
bated at 37°C for 10min. The reaction was then stopped with 100ml
of assay buffer containing 7.5mMEDTA. A total of 40ml of spec-
trozyme Xa was added and the rate of factor Xa generation, which is
proportional to the amount of TF expressed by monocytes, was
determined by measuring the increase in the absorbance of the free
chromophore pNA generated in comparison to the original
substrate. Absorbance values were automatically calculated by the
Kinetic-Calc™package based on the standard curve constructed
from serial dilutions of recombinant relipidated TF (0.75–83.0ng
ml–1) and converted to TF (ng10–6 cells). The recombinant TF was
obtained from the American Diagnostica Inc, Greenwich, CT, USA.
Relipidation was performed in our laboratory according to the
method of Carson and Konigsberg (1980). The standard curve is set
out on each microplate for each set of measurements. Results were
then multiplied by 5 and expressed as ng TF 10–6 mononuclear cells
per well (each well contained 2 ´106 cells).
Statistical analysis
Data were included in a database and analysed by the STAT-
GRAPHICS™statistical software system. Data were not normally
distributed, and summary statistics were expressed as medians and
interquartile ranges (IQR). Differences between two groups were
assessed by the Mann–Whitney U-test. Differences in tumour
grading were tested by Kruskal–Wallis one-way analysis by ranks.
280 BA Lwaleed et al
British Journal of Cancer (1999) 80(1/2), 279–285 © Cancer Research Campaign 1999
Table 1Sample size of monocyte tissue factor activity, median and age range and sex for all groups studied for the neoplastic diseases
Group n Median age (years) Age range Male Female
(n)( n)
Normalsa 60 35 19–77 26 34
Cholecystectomy or hernia 60 61 30–86 43 17
Breast benign non-inflammatory 21 42 20–74 – 21
Breast benign inflammatoryb 4 57 42–76 – 4
Breast cancer 58 63 35–87 – 58
Colorectal benign non-inflammatory 31 66 39–92 16 15
Colorectal benign inflammatoryc 13 60 44–89 7 6
Colorectal cancer 18 73 46–85 8 10
aHospital staff; bmastitis and mammary duct ectasia; culcerative colitis and diverticulitis.Monocyte tissue factor activity in patients with cancer 281
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Figure 1 Monocyte tissue factor activity (ng 10–6 cells) in normal controls, patients undergoing hernia repair or cholecystectomy, non-inflammatory and
inflammatory benign disease, and malignant disease of the breast, for baseline (resting), after 6 h incubation without endotoxin (unstimulated cells) and after
6 h incubation with endotoxin (stimulated cells)RESULTS
Assessment of monocyte tissue factor activity in
breast and colorectal cancer
The median and IQR of mTF activity for breast and colorectal
diseases are shown in Figures 1 and 2 and statistical comparisons
detailed in Table 2.
In the breast disease groups (Figure 1), there was no significant
difference between the normal and the other two control groups
(hernia or cholecystectomy, and benign non-inflammatory breast
disease). Inflammatory benign disease showed an elevation in
mTF levels compared with each control group for the stimulated
cells only. Although the numbers in the inflammatory group were
small, the statistical test gave P < 0.01. On the other hand, the
malignant groups showed variable significant increases over the
control groups for the baseline, unstimulated and the stimulated
cells (Table 2). There was no significant difference between the
benign inflammatory group and the malignant group for all the
three parameters studied.
For colorectal disease (Figure 2), the three control groups
displayed no significant differences when tested against each
other. The inflammatory benign disease group showed signifi-
cantly raised mTF over all controls for baseline (P < 0.05), un-
stimulated (P < 0.05) and stimulated cells (P < 0.01). Malignancy
conferred a significant increase over each control group for all
mTF parameters measured; baseline (P < 0.05), unstimulated (P <
0.05) and stimulated cells (P < 0.01). Table 2 includes all relevant
P-values. No significant difference was observed between benign
inflammatory and malignant patients.
mTF in patients with breast malignancy gave results above the
upper quartile range of the normal controls for resting 46.6%,
unstimulated 32.8% and stimulated cells 61.9%, while patients
with colorectal cancer showed 33.9% for resting, 33.3% unstimu-
lated and 66.7% stimulated cells. The stimulated mTF activity of
the colorectal group showed the highest increase compared with
controls or patients with breast malignancy (Figure 3).
Tumour grade or stage
Tumour grading was carried out according to histological criteria.
There is an increase in mTF corresponding to a higher tumour
grade or stage. This trend did not reach statistical significance for
resting, unstimulated or LPS-stimulated cells (Kruskal–Wallis).
Patient survival
There was a trend towards decreased mTF activity in longer
surviving patients with malignancy. Again, the differences were
not statistically significant (Mann–Whitney).
DISCUSSION
Using a two-stage KCA for mTF measurements, patients with
malignant tumours showed significant increases in mTF levels
when compared with the controls or the relevant benign non-
inflammatory conditions. Similarly, patients with inflammatory
conditions (mastitis, mammary duct ectasia, ulcerative colitis and
diverticulitis) showed significantly increased mTF levels when
compared with controls or benign non-inflammatory disease
groups. No significant differences were observed between the
appropriate benign inflammatory and malignant disease groups.
However, the numbers of inflammatory breast disease accrued
were small and should not be over-interpreted. These results agree
with those reported by Carvalho (1995) and for urinary TF activity
by Lwaleed et al (1999).
Inflammatory conditions are known to enhance mTF expression
(Hogg, 1983) and isolated monocytes from patients with Crohn’s
disease were noticed to express elevated levels of mTF (Edwards
et al, 1987). When the benign groups of the present study were
sub-divided into organ-specific non-inflammatory and inflamma-
tory diseases, the former group showed comparable levels with the
controls. Patients undergoing hernia repair and cholecystectomy
who had a normal ESR also showed a low variation in mTF levels
equivalent to that of the normal control groups. Similar results
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Table 2 Differences in monocyte tissue factor between normal controls and various disease categories
Normal Breast B- Breast Breast Colorectal Colorectal Colorectal
Non-Inf B-Inf cancer B-Non-Inf B-Inf cancer
Normal – NS NS < 0.01 NS < 0.05 < 0.05
– NS NS < 0.05 NS < 0.05 < 0.05
– NS < 0.01 < 0.001 NS < 0.01 < 0.01
Hernia and Chole NS NS NS < 0.01 NS < 0.05 < 0.05
NS NS NS < 0.01 NS < 0.05 < 0.05
NS NS < 0.01 < 0.001 NS < 0.01 < 0.01
Breast NS – NS < 0.05 – – –
B-Non-Inf NS – NS < 0.05 – – –
NS – < 0.01 < 0.001 – – –
Colorectal NS – – – – < 0.05 < 0.05
B-Non-Inf NS – – – – < 0.01 < 0.01
NS – – – – < 0.01 < 0.01
Chole = Cholecystectomy; Inf = inflammatory; NS = not significant. B = benign; Inf = Iinflammatory; – not applicable. Each group has three values of P (or NS
when P < 0.05): Top = baseline (resting), middle = after 6 h incubation without endotoxin (unstimulated cells) and bottom = after 6 h incubation with endotoxin
(stimulated cells).Monocyte tissue factor activity in patients with cancer 283
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Figure 2 Monocyte tissue factor activity (ng 10–6 cells) in normal controls, patients undergoing hernia repair or cholecystectomy, non-inflammatory and
inflammatory benign disease, and malignant disease of the colorectum, for baseline (resting), after 6 h incubation without endotoxin (unstimulated cells) and
after 6 h incubation with endotoxin (stimulated cells)have been reported (Dasmahapatra et al, 1987; Carvalho, 1995)
and these get further support by immunohistochemical and in situ
detection studies (Contrino et al, 1996). It appears that TF assays
respond with equal sensitivity to the benign inflammatory and
malignant conditions and the link might be immunologically
mediated (Edwards et al, 1987; Hogg, 1983; Østerud et al, 1990).
Although inflammatory and malignant conditions showed
increased levels of mTF as compared with the controls, there was
an overlap between the groups. This may have been exacerbated
by factors such as the heterogeneity of the various groups,
including the stage of evolution of the disease or treatment sched-
ules. All patients on anticoagulant and/or steroids were excluded
from the study. However, of the patients with Crohn’s disease
treated with prednisolone inadvertently studied and retrospectively
excluded, few showed normal mTF levels.
A comparison of the three levels of mTF activity measured
(baseline, unstimulated and stimulated) shows that the latter
discriminates better between the groups studied, consistent with
the previous reports (Dasmahapatra et al, 1987; Carvalho 1995).
Despite the fact that stimulated mTF levels gave the best results
this perhaps reflects not only the in vivo condition, but possibly
changes in the cellular phospholipid compositions caused by LPS
in vitro. TF activity is known to depend greatly on the composition
of complexed phospholipid (Nemerson and Gentry, 1986). In that
respect, baseline mTF activity may be more physiologically rele-
vant. Unlike the stimulated levels, baselines are closely associated
with the antigenic levels measured by flow cytometry (Carvalho,
1995). However, both levels may be required in assessing the PCA
of mTF in disease states (Francis et al, 1995).
A previous study showed no relationship between tumour grade
or stage and mTF levels (Carvalho, 1995) and it was postulated
that elevated mTF levels are present from the initial growth of the
primary tumour. However, the incidence of clotting abnormalities
rises as the disease progresses (Naschitz, 1996) and the present
study demonstrated an increase in the mTF levels associated with
tumour grade or stage. This is particularly true for the colorectal
group where patients with Dukes’ B and C had higher mTF levels
than Dukes’ A.
Although mTF levels increased in the tumours studied, a greater
increase was observed for colorectal cancer as compared to breast
tumour. While it is known that colorectal cancer expresses
elevated levels of cellular TF (Szczepanski, 1988) and that higher
levels of free TF were observed for colorectal tissues compared to
breast tissues (El-Baruni, 1990), there is no obvious reason to
explain this phenomenon. Inflammation is also known to signifi-
cantly enhance mTF production and colorectal cancer is often
associated with ulceration and bacterial infection which is known
to stimulate mTF expression (Østerud and Flaegstad, 1983).
Another important factor which may have contributed to this
finding is that most colon cancer patients present at a later stage of
disease progression and the tumours are physically larger, particu-
larly in relation to breast cancer which is subject to screening.
There was a trend towards decreased mTF activity in longer
surviving patients with malignancy, as reported previously
(Carvalho, 1995). These results are also consistent with the finding
that mTF activity increased with tumour grade or stage.
In conclusion, LPS enhances mTF activity and stimulated cells
can better distinguish patients with cancer from normal controls
and benign diseases in the absence of inflammation. Thus LPS-
stimulated mTF levels may play a role in screening patients that
are at risk and most likely to benefit from further investigation for
cancer. mTF levels were raised in patients with higher tumour
grade or stage. This suggests a role for mTF levels in assessing
tumour progression and response to treatment.
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